Dr Andrew David Morris, MD | |
700 West Ave S, La Crosse, WI 54601-4783 | |
(608) 785-0940 | |
Not Available |
Full Name | Dr Andrew David Morris |
---|---|
Gender | Male |
Speciality | General Surgery |
Experience | 11 Years |
Location | 700 West Ave S, La Crosse, Wisconsin |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194068320 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 20855 (Wisconsin) | Secondary |
208C00000X | Colon & Rectal Surgery | 75897 (Wisconsin) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Mayo Clinic Health System-franciscan Medical Center Inc | La crosse, WI | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mayo Clinic Health System-franciscan Medical Center Inc | 0345152443 | 419 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.
New research from Brigham Young University finds that patients who undergo gastric bypass surgery after the age of 35 see a major improvement in long-term survival.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
› Verified 4 days ago
Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20031110000684 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.
New research from Brigham Young University finds that patients who undergo gastric bypass surgery after the age of 35 see a major improvement in long-term survival.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
› Verified 4 days ago
Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
---|---|
Entity Type | Part A Provider - Critical Access Hospital |
Entity Identifiers | NPI Number: 1841278637 PECOS PAC ID: 0345152443 Enrollment ID: O20100506000523 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.
New research from Brigham Young University finds that patients who undergo gastric bypass surgery after the age of 35 see a major improvement in long-term survival.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Andrew David Morris, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (608) 785-0940 | Dr Andrew David Morris, MD 700 West Ave S, La Crosse, WI 54601-4783 Ph: (608) 785-0940 |
News Archive
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the "Units"), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Royal Philips Electronics today announced the enhanced iE33 xMATRIX cardiac ultrasound system featuring a new ergonomic solution for more efficient adult echocardiograms, the X5-1 transducer. With this enhanced technology, Philips continues its tradition of simplified, patient-focused healthcare solutions by providing a more complete imaging solution.
New research from Brigham Young University finds that patients who undergo gastric bypass surgery after the age of 35 see a major improvement in long-term survival.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received 510(k) clearance from the Food and Drug Administration (FDA) for a five-year shelf-life on its CryoPatch® SG pulmonary human cardiac patch processed with the Company's proprietary SynerGraft® technology. CryoLife's SynerGraft technology is designed to remove allogeneic donor cells and cellular remnants from tissue without compromising the integrity of the underlying collagen matrix.
› Verified 4 days ago